Carfilzomib and the cardiorenal system in myeloma: An endothelial effect?

Blood Cancer Journal

Volumn 6, Issue 1, 2016, Pages

  Rosenthal, A ^a   Luthi, J ^a   Belohlavek, M ^a   Kortum K M ^a   Mookadam, F ^a   Mayo, A ^a   Fonseca, R ^a   Bergsagel, P L ^a   Reeder, C B ^a   Mikhael, J R ^a   Stewart, A K ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; CARFILZOMIB; OLIGOPEPTIDE; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76); PROTEASOME INHIBITOR;

ADULT; AGED; CARDIOTOXICITY; COMPLICATION; DRUG EFFECTS; FEMALE; HEART DISEASES; HEART STROKE VOLUME; HUMAN; KIDNEY DISEASES; MALE; METABOLISM; MIDDLE AGED; MULTIPLE MYELOMA; PATHOLOGY; PATHOPHYSIOLOGY;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS; CARDIOTOXICITY; FEMALE; HEART DISEASES; HUMANS; KIDNEY DISEASES; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NATRIURETIC PEPTIDE, BRAIN; OLIGOPEPTIDES; PEPTIDE FRAGMENTS; PROTEASOME INHIBITORS; STROKE VOLUME;

EID: 84986296809     PISSN: None     EISSN: 20445385     Source Type: Journal    
DOI: 10.1038/bcj.2015.112     Document Type: Article

References (20)

1. Nowis D, Mączewski M, Mackiewicz U, Kujawa M, Ratajska A, Wieckowski MR et al. Cardiotoxicity of the anticancer therapeutic agent bortezomib. Am J Pathol 2010;176:2658-2668.
2. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Eng J Med 2005;352:2487-2498.
3. Honton B, Despas F, Dumonteil N, Rouvellat C, Roussel M, Carrie D et al. Bortezomib and heart failure: case-report and review of the French Pharmacovigilance database. Fundam Clin Pharmacol 2014;28:349-352.
4. Subedi A, Sharma L, Shah B. Bortezomib-induced acute congestive heart failure: a case report and review of literature. Ann Hematol 2014;93:1797-1799.
5. Demo S, Kirk C, Aujay M, Buchholz T, Dajee M, Ho M et al. Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res 2007;67:6383-6391.
6. Arastu-Kapur S, Anderl J, Kraus M, Parlati F, Shenk K, Lee S et al. Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events. Clin Cancer Res 2011;17:2734-2743.
7. Vij R, Siegel DS, Jagannath S, Jakubowiak AJ, Stewart AK, McDonagh K et al. An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib. Br J Haematol 2012;158:739-748.
8. Kortuem KM, Stewart AK. Carfilzomib. Blood 2013;121:893-897.
9. Jagannath S, Vij R, Stewart AK, Trudel S, Jakubowiak AJ, Reiman T et al. An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, singleagent carfilzomib in patients with relapsed and refractory multiple myeloma. Clin Lymphoma Myeloma Leuk 2012;12:310-318.
10. Siegel D, Martin T, Wang M, Vij R, Jakubowiak A, Lonial S et al. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood 2012;120:2817-2825.
11. Siegel D, Martin T, Nooka A, Harvey RD, Vij R, Niesvizky R et al. Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies. Haematologica 2013;98:1753-1761.
12. Stewart AK, Rajkumar SV, Dimopoulos MA, Masszi T, Špicka I, Oriol A et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Eng J Med 2015;372:142-152.
13. Mikhael JR, Reeder CB, Libby EN, Costa LJ, Bergsagel PL, Buadi F et al. Phase Ib/II trial of CYKLONE (cyclophosphamide, carfilzomib, thalidomide and dexamethasone) for newly diagnosed myeloma. Br J Haematol 2015;169:219-227.
14. Raymond I, Groenning BA, Hildebrandt PR, Nilsson JC, Baumann M, Trawinski J et al. The influence of age, sex and other variables on the plasma level of N-terminal pro brain natriuretic peptide in a large sample of the general population. Heart 2003;89:745-751.
15. Anwaruddin S, Lloyd-Jones DM, Baggish A, Chen A, Krauser D, Tung R et al. Renal function, congestive heart failure, and amino-terminal pro-brain natriuretic peptide measurement: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Study. J Am Coll Cardiol 2006;47:91-97.
16. Grandin EW, Ky B, Cornell RF, Carver J, Lenihan DJ. Patterns of cardiac toxicity associated with irreversible proteasome inhibition in the treatment of multiple myeloma. J Card Fail 2015;21:138-144.
17. Ludwig H, Masszi T, Pertucci MT, Palumbo A, Rosinol L, Nagler A et al. Carfilzomib vs low-dose corticosteroids and optional cyclophosphamide in patients with relapsed and refractory multiple myeloma: A phase 3 study (FOCUS). Ann Oncol 2014;25.
18. Dimopoulos MA, Moreau P, Palumbo A, Joshua DE, Pour L, Hajek R et al. Carfilzomib and dexamethasone (Kd) vs bortezomib and dexamethasone (Vd) in patients (pts) with relapsed multiple myeloma (RMM): Results from the phase III study ENDEAVOR. J Clin Oncol (ASCO Meeting Abstracts) 2015;33:8509.
19. Jagannath S, Vij R, Kaufman JL, Martin T, Niesvizky R, Gabrail NY et al. Long-term treatment and tolerability of the novel proteasome inhibitor carfilzomib (cfz) in patients with relapsed and/or refractory multiple myeloma (R/R MM). Blood (ASH Annual Meeting Abstracts) 2010;116:1953.
20. Ludwig H, Durie BGM, McCarthy P, Palumbo A, San Miguel J, Barlogie B et al. IMWG consensus on maintenance therapy in multiple myeloma. Blood 2012;119:3003-3015.